Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFFITOPE PD01A and PD03A in Early Multiple System Atrophy
NCT02270489Phase 1Completed
- Sponsor
- AFFiRiS
- Start
- Dec 2014
- Primary completion
- Apr 2017
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AFFITOPE PD03A in multiple system atrophy (MSA) (3 arms), sponsored by AFFiRiS. Primary endpoints: Number of patients who withdraw due to Adverse Events at 12 months, Occurrence of Adverse Events and Serious Adverse Events at 12 months and 6 more. Started Dec 2014; status: completed.
02
Drugs
AFFITOPE PD03A
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT02270489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02270489.